Gottsdanker v. Cutter Laboratories

182 Cal. App. 2d 602, 6 Cal. Rptr. 320, 79 A.L.R. 2d 290, 1960 Cal. App. LEXIS 2152
CourtCalifornia Court of Appeal
DecidedJuly 12, 1960
DocketDocket Nos. 18413, 18414
StatusPublished
Cited by75 cases

This text of 182 Cal. App. 2d 602 (Gottsdanker v. Cutter Laboratories) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gottsdanker v. Cutter Laboratories, 182 Cal. App. 2d 602, 6 Cal. Rptr. 320, 79 A.L.R. 2d 290, 1960 Cal. App. LEXIS 2152 (Cal. Ct. App. 1960).

Opinion

DRAPER, J.

Two children contracted poliomyelitis shortly after being inoculated with Salk vaccine manufactured by defendant. On the premise that defendant’s vaccine caused the illness it was designed to prevent, an action for damages was brought in behalf of each child. The actions were consolidated for trial. Jury verdicts were in favor of the two children for a total of $139,000, and for their parents for $8,300 in special damages.

There is substantial evidence to sustain a finding that the vaccine contained live virus of poliomyelitis, and that the injected vaccine caused the disease in each child. The essence of plaintiffs’ claim is not that the vaccine failed to prevent' polio, but that it actually and directly caused it.

Three causes of action were submitted to the jury in each case. One was in negligence, one for breach of an implied warranty of merchantability and one for breach of implied warranty of fitness for the intended purpose. But only two forms of verdict were presented to the jury in each case, one for the plaintiff generally, without separation of the causes of action, and one for the defendant.

In returning its verdicts for plaintiffs, however, the jury drew a thoughtful and careful statement, setting forth that the jury had first considered the issue of negligence, and had “from a preponderance of the evidence concluded that the defendant, Cutter Laboratories, was not negligent either directly or by inference. ’ ’

“With regard to the law of warranty, however, we feel that* we have no alternative but to conclude that Cutter Laboratories'; came to market . . . vaccine which when given to plaintiffs caused them to come down with poliomyelitis, thus resulting in a breach of warranty. For this cause alone we find in favor of plaintiffs.”

In accordance with this jury statement, judgments were entered in favor of plaintiffs on the two causes of action for breach of implied warranty, and in favor of defendant on the counts for negligence. Defendant appeals from the judgments against it. Plaintiffs appeal from the judgments against them on the causes of action for negligence, asserting that the jury’s written statement must be disregarded as sur *606 plusage, leaving only the signed verdict forms in favor of plaintiffs on the complaints generally, and that the evidence is insufficient to support verdicts against plaintiffs on the issue of negligence.

Defendant’s appeal squarely presents the question whether implied warranties of merchantability and of fitness apply under the facts of this case.

The vaccine administered to each child was purchased by a doctor from a pharmacy in a sealed bottle or ampule. In one case the hypodermic injection of the vaccine was made by a doctor, in the other by a nurse under a doctor’s direction. Neither doctor was joined as a defendant. One pharmacy was joined, but later dismissed. Thus the judgments are against defendant pharmaceutical manufacturer only.

A principal question is whether defendant manufacturer can be liable upon implied warranty in the absence of direct sale from it to plaintiffs. Historically, liability in implied warranty sounds in tort, and it can be reasoned that the true basis of such recovery now lies in tort, rather than contract (see Prosser on Torts, 2d ed., 493). Nonetheless, “privity of contract’’ (i.e., direct sale from defendant to plaintiff) remains a requirement for implied warranty liability in substantially all American jurisdictions. This rule is followed in California as to most manufactured products (Burr v. Sherwin-Williams Co., 42 Cal.2d 682 [268 P.2d 1041]), although the modern trend is to modify the strictness of the requirement in some situations (Peterson v. Lamb Rubber Co., 54 Cal.2d 339 [5 Cal.Rptr. 863, 353 P.2d 575]). However, where the product is food for human consumption, a number of jurisdictions have recognized an exception to the privity requirement. In such cases, it is held that the manufacturer or initial seller may be held liable to the ultimate consumer even though there have been intermediate sales by one or more dealers. Although this is the minority rule, it is followed in some 15 to 18 states. (Prosser on Torts, 2d ed., 508-9; 1 Williston on Sales, rev. ed., 647-8.)

California clearly accepted this exception in 1939. (Klein v. Duchess Sandwich Co., Ltd., 14 Cal.2d 272 [93 P.2d 799].) The court flatly rejected the contention that an implied warranty in food cases runs “only from an immediate seller to an immediate buyer. ’ ’ The court reviewed cases from other jurisdictions and pointed out that varying theories are advanced in support of the exception. Klein particularly .emphasizes the public policy of requiring that only wholesome food be sold for human consumption. The rule continues *607 to be followed in California. (Vaccarezza v. Sanguinetti, 71 Cal.App.2d 687 [163 P.2d 470].)

In view of the established California rule that the consumer of a food product may recover from the manufacturer upon implied warranty, is there any reason to apply a different rule to the vaccine here involved? We think not. The vaccine is intended for human consumption quite as much as is food. We see no reason to differentiate the policy considerations requiring pure and wholesome food from those requiring pure and wholesome vaccine. Some significance may attach to the fact that Klein (p. 277) quotes a decision (Ra chlin v. Libby-Owens-Ford Glass Co., 96 F.2d 597, 600) which states that the privity exception extends to “medicines and foodstuffs.” Klein also relies upon the several pure food and drug acts as indicating the public policy which underlies the rule. We can conceive of no reason for applying the rule to foodstuffs which does not equally extend to drugs. The vaccine here involved is, like food products, designed solely for introduction into the body of a human being.

The fact that the entry is made by injection rather than ingestion in no way alters the premise that each is for human consumption—each enters the human system. In fact, the digestive system has means of rejecting or minimizing the effects of many toxic compounds taken orally. Such defenses are much less available as against harmful elements introduced into the system by hypodermic injection.

We find no decision directly upon the point. Defendant cites trial court decisions from other jurisdictions (Russo v. Merck & Co., 138 F.Supp. 147; Wechsler v. Hoffman-La Roche, Inc., 99 N.Y.S.2d 588; Dumbrow v. Ettinger, 44 F.Supp. 763) holding that blood plasma or drugs are within the privity requirement. But all these jurisdictions apply the requirement of privity in all implied warranty cases, without exception.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Grausz v. The Hershey Company
S.D. California, 2024
Shay v. Apple, Inc.
S.D. California, 2021
Tapia v. Davol, Inc.
116 F. Supp. 3d 1149 (S.D. California, 2015)
Rader v. TEVA PARENTAL MEDICINES, INC.
795 F. Supp. 2d 1143 (D. Nevada, 2011)
Clemens v. Daimlerchrysler
Ninth Circuit, 2008
Clemens v. DaimlerChrysler Corp.
530 F.3d 852 (Ninth Circuit, 2008)
Arnold v. Dow Chemical Company
110 Cal. Rptr. 2d 722 (California Court of Appeal, 2001)
Murphy v. E. R. Squibb & Sons, Inc.
710 P.2d 247 (California Supreme Court, 1985)
Kearl v. Lederle Laboratories
172 Cal. App. 3d 812 (California Court of Appeal, 1985)
Finn v. G. D. Searle & Co.
677 P.2d 1147 (California Supreme Court, 1984)
Sheffield v. Eli Lilly & Co.
144 Cal. App. 3d 583 (California Court of Appeal, 1983)
Jones v. Superior Court
119 Cal. App. 3d 534 (California Court of Appeal, 1981)
McDonald v. Sacramento Medical Foundation Blood Bank
62 Cal. App. 3d 866 (California Court of Appeal, 1976)
Reyes v. Wyeth Laboratories
498 F.2d 1264 (Fifth Circuit, 1974)

Cite This Page — Counsel Stack

Bluebook (online)
182 Cal. App. 2d 602, 6 Cal. Rptr. 320, 79 A.L.R. 2d 290, 1960 Cal. App. LEXIS 2152, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gottsdanker-v-cutter-laboratories-calctapp-1960.